Urticaria Clinical Trials

A listing of Urticaria medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 49 clinical trials
A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (PEARL-PROVOKE)

This is a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1

  • 8 views
  • 18 Oct, 2022
  • 51 locations
The Association Between Human Microbiome and Vitamin D in Chronic Urticaria

A double-blind study to evaluate the role of human microbiome and vitamin D in the development of urticaria.

Accepts healthy volunteers
chronic urticaria
  • 2 views
  • 07 Oct, 2022
  • 1 location
An Open-label, Multicenter Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effects of THB001 in Adult Patients With Chronic Cold Urticaria

This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.

  • 0 views
  • 21 Oct, 2022
  • 2 locations
: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria

  • 7 views
  • 22 Oct, 2022
  • 14 locations
Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid

joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine

Accepts healthy volunteers
  • 0 views
  • 14 Oct, 2022
COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)

To evaluate if omalizumab is effective in decreasing mortality in severe hospitalized COVID-19 cases.

  • 0 views
  • 04 Oct, 2022
  • 3 locations
A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects With Indolent Systemic Mastocytosis

Background Mast cells help the body fight disease and heal wounds. People with indolent systemic mastocytosis (ISM) make too many mast cells. This causes pain, tiredness, digestive problems, and other symptoms. Researchers think the drug sarilumab could help. Objective To see if sarilumab is a safe and effective treatment for …

  • 62 views
  • 13 Oct, 2022
  • 1 location
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B (BEe-HIVe)

The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.

engerix-b
HIV Vaccine
vaccination
  • 20 views
  • 27 Oct, 2022
  • 28 locations
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU. After

  • 0 views
  • 07 Oct, 2022
  • 29 locations
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately

  • 8 views
  • 04 Oct, 2022
  • 110 locations